GSK (GSK) News Today GBX 1,310 +10.00 (+0.77%) (As of 05:49 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period GSK announces phase III trial of linerixibat met primary endpointNovember 20 at 11:30 AM | markets.businessinsider.comDown 28%! What’s going on with GSK’s share price?November 20 at 11:30 AM | uk.finance.yahoo.comGSK reports positive Phase 3 results for linerixibat in PBC itchingNovember 19 at 1:40 PM | msn.comGSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some PatientsNovember 19 at 1:40 PM | finance.yahoo.comFTSE 100 Live 15 November: GDP disappoints, fresh GSK slump offsets Land Securities upgradeNovember 16, 2024 | msn.comGSK reports positive outcomes from Phase III multiple myeloma treatment trialNovember 16, 2024 | msn.comGSK hails progress for withdrawn blood cancer drugNovember 14, 2024 | ft.comGSK’s Withdrawn Blood Cancer Drug Reduced Risk of Death in TrialNovember 14, 2024 | bloomberg.comGSK Reports Positive Headline Results From DREAMM-7 Phase III TrialNovember 14, 2024 | markets.businessinsider.comGSK plc (LON:GSK) Insider Julie Brown Purchases 8 SharesNovember 13, 2024 | insidertrades.comGSK (LON:GSK) Hits New 1-Year Low - Should You Sell?GSK (LON:GSK) Reaches New 1-Year Low - Should You Sell?November 12, 2024 | marketbeat.comGSK price target lowered to 1,450 GBp from 1,550 GBp at BarclaysNovember 9, 2024 | markets.businessinsider.comGSK CEO addresses declining trust in vaccines following Trump re-electionNovember 6, 2024 | finance.yahoo.comGSK’s RSV vaccine approved in Canada for adults aged 50 to 59November 6, 2024 | finance.yahoo.comGlaxoSmithKline (GSK) Receives a Buy from BernsteinOctober 31, 2024 | markets.businessinsider.comGSK plc (LON:GSK) Receives Average Recommendation of "Moderate Buy" from BrokeragesGSK plc (LON:GSK - Get Free Report) has earned an average rating of "Moderate Buy" from the seven brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buyOctober 31, 2024 | marketbeat.comGSK plc (LON:GSK) Insider Buys £99,671 in StockOctober 31, 2024 | insidertrades.comGSK plc (LON:GSK) to Issue GBX 15 DividendGSK plc (LON:GSK) announced a dividend on Wednesday, October 30th. Shareholders of record on Thursday, November 14th will be given a dividend of GBX 15 ($0.19) per share on Thursday, January 9th. This represents a yield of 1.03%. The ex-dividend date is Thursday, November 14th. The official announcement can be viewed at this link.October 30, 2024 | marketbeat.comBritish pharmaceutical company GSK reports drop in Q3 pre-tax profitOctober 30, 2024 | msn.comGSK Profit Rises on HIV, Cancer Treatments But Sales Slip on Weak U.S. Vaccine DemandOctober 30, 2024 | msn.comGSK reiterates guidance as HIV and cancer drug demand offset vaccine weaknessOctober 30, 2024 | msn.comGSK’s Vaccine Sales Drop, Taking the Shine off Strong ProfitOctober 30, 2024 | bloomberg.comGSK cuts 2024 vaccine sales forecast for second time this yearOctober 30, 2024 | msn.comGSK to acquire CMG1A46 from Chimagen BiosciencesOctober 29, 2024 | markets.businessinsider.comGSK inks deal to buy lupus therapy from Chimagen for USD300 millionOctober 29, 2024 | lse.co.ukGSK Inks Lupus Deal With Chinese Biotech for Up to $850 MillionOctober 29, 2024 | msn.comGraham Parry Issues ‘Sell’ Rating on GlaxoSmithKline Amid Declining Vaccine Sales and EPS Forecast CutsOctober 29, 2024 | markets.businessinsider.comGSK stays in red for seven straight sessionsOctober 25, 2024 | msn.comGSK invests $800M in manufacturing; Amgen sets small discount for Eylea biosimilarOctober 25, 2024 | finance.yahoo.comGSK pumps up to $800m for US manufacturing site upgradeOctober 25, 2024 | finance.yahoo.comGSK to invest up to $800M in Pennsylvania siteOctober 25, 2024 | markets.businessinsider.comGSK plans $800M expansion of Pennsylvania drug manufacturing facilitiesOctober 25, 2024 | bizjournals.comGSK investing up to $800 million in Lancaster County facility expansionOctober 24, 2024 | msn.comHaleon: Too Vanilla For My Liking - I See Why GSK & Pfizer Wanted OutOctober 24, 2024 | seekingalpha.comUBS Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)October 22, 2024 | markets.businessinsider.comBoston University and GSK collaborate to tackle pulmonary fibrosisOctober 17, 2024 | msn.comGSK rises Thursday, still underperforms marketOctober 17, 2024 | marketwatch.comGSK sues Moderna over mRNA vaccine technologyOctober 16, 2024 | msn.comGSK’s AREXVY Vaccine Shows Promising Results Across Three RSV SeasonsOctober 14, 2024 | msn.comGSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One YearOctober 14, 2024 | finance.yahoo.comGSK’s problem is it has more than one source of painOctober 10, 2024 | ft.comGSK to Resolve 93% of U.S. State Court Zantac Product Liability Cases for Up to $2.2BOctober 9, 2024 | marketwatch.comGSK reaches $2.2bn heartburn medication Zantac settlement in USOctober 9, 2024 | ft.comGSK Resolves Majority Of US Zantac Cases With $2.2B Settlement Deal, Stock SurgesOctober 9, 2024 | finance.yahoo.comGSK to Settle 80,000 Zantac Cases for Up to $2.2 BillionOctober 9, 2024 | msn.comGSK reaches up to $2.2 billion settlement in Zantac US state court casesOctober 9, 2024 | reuters.comGSK Reached Agreements With 10 Plaintiff Firms Over Zantac LitigationOctober 9, 2024 | msn.comGlaxoSmithKline (GSK) Receives a Hold from Goldman SachsOctober 9, 2024 | markets.businessinsider.comGSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV SeasonsOctober 8, 2024 | finance.yahoo.comGSK Announces Positive Data From AReSVi-006 Phase III Trial For RSV Vaccine ArexvyOctober 8, 2024 | markets.businessinsider.com Get GSK News Delivered to You Automatically Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run… All you have to do is follow this link here GSK Media Mentions By Week GSK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GSK News Sentiment▼0.540.45▲Average Medical News Sentiment GSK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GSK Articles This Week▼86▲GSK Articles Average Week Get GSK News Delivered to You Automatically Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AZN News Today HCM News Today ITH News Today GRI News Today INDV News Today BMY News Today GPH News Today IGC News Today PHAR News Today KOD News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:GSK) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK plc Please log in to your account or sign up in order to add this asset to your watchlist. Share GSK With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
